+91 8617752708

British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 21, Issue.: 10


Longevinex ® Improves Human Atrophic Aged-related Macular Degeneration (AMD) Photoreceptor / Retinal Pigment Epithelium Mediated Dark Adaptation*


Stuart Richer1,2,3*, Lawrence Ulanski II1,3, Anish Bhandari4,5 and Natalia Popenko4,5

1Departments of Optometry and Ophthalmology, Preventative Ocular Medicine and Residencies, USA.

2Family Medicine, Chicago Medical School, Rosalind Franklin University of Medicine and Science (RFUMS), North Chicago, IL 60064-3095, USA.

3Department Surgery, UIC Eye and Ear Infirmary, Ophthalmology Retina Service 60612 USA.

4Captain James A Lovell Federal Health Care, North Chicago, IL, 60064-3095 USA.

5Chicago Medical School, Rosalind Franklin University of Medicine and Science (RFUMS), North Chicago, IL, 60064-3095 USA.

Article Information
(1) Thiago Goncalves dos Santos Martins, Department of Ophthalmology, Federal University of Sao Paulo, Brazil.
(1) Thiago Gonçalves dos Santos Martins, Federal University of São Paulo, Brazil.
(2) Asaad Ahmed Ghanem, Mansoura University, Egypt.
Complete Peer review History: http://www.sciencedomain.org/review-history/19286


Aim: Gradual photoreceptor/ RPE deterioration/ vision loss in AMD is common, irrespective of US NEI AREDS I/II supplement risk reduction, or intra-vitreal anti-VEGF pharmacology. We evaluated dark adaptation (DA), a broad measure of photoreceptor / RPE health, with / without epigenetic modulation using a resveratrol–based caloric-restriction mimic (Longevinex ®www.longevinex.com).

Study Design: Case series, bi-ocular, clinical DA evaluation in deteriorating AMD, before and after supplementation, under medical center compassionate use guidelines.

Place and Duration of Study: Captain James A Lovell Federal Health Care Center, Illinois, USA, Optometry/Ophthalmology Departments between 4/2015 and 8/2016.

Methods: Baseline clinical DA threshold (log DB), time (min), and fixation (%) were taken for patients with established atrophic AMD (n=14 eyes; 6 M / 1 F; ages 64 - 89 years), using the AdaptDx ® (www.maculogix.com), with pupil dilation and best refraction. Following prescription of Longevinex® 1 capsule qd AM, DA was repeated, with each eye’s response considered independent.

Results: All but 2 eyes improved in one or more DA parameters, with 3 cases showing improvement by retinal macula SD OCT. Expected vs. actual (worse vs. same/better), by eye, was significant by Chi Square, P < .01. Additional factors affecting DA: smoking, alcohol, elevated CRP and statins were retrospectively evaluated.

Conclusion: These first cases of epigenetic-induced DA stability / improvement are consistent with previous beneficial effects of Longevinex® such as enhanced choriocapillaris circulation. DA is the earliest functional AMD sign and a prime candidate for “AMD prevention”. This work merits expansion to controlled studies.

Keywords :

AMD; dark adaptation; epigenetics; Longevinex®; resveratrol.

Full Article - PDF    Page 1-19

DOI : 10.9734/BJMMR/2017/33820

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,

+91 8617752708


Third Floor, 207 Regent Street
London, W1B 3HH,

+44 20-3031-1429